Smith Julie
SEC insider (Form 3/4/5 filer). CIK 0001557928. Director at Stoke Therapeutics, Inc. (STOK) and 1 other issuer. 15 reported Form 4/5 transactions since Sep 2024; latest on Jun 3, 2026. Located in BEDFORD, MA.
Companies Smith Julie has filed insider reports for
- Stoke Therapeutics, Inc. (STOK): Director
- EXELIXIS, INC. (EXEL): Director
Smith Julie
CIK: 0001557928
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (15 total)
- Jun 3, 2026STOK
Stoke Therapeutics, Inc.
AwardDirectDirector Stock Option (Right to Buy)
17.8K shares- - May 27, 2026EXEL
EXELIXIS, INC.
AwardDirect8.4K shares- - Feb 18, 2026EXEL
EXELIXIS, INC.
ExerciseDirect44.1K shares at avg. $19.39$855K - Feb 18, 2026EXEL
EXELIXIS, INC.
SaleDirect20K shares at avg. $44.30$887K - Feb 18, 2026EXEL
EXELIXIS, INC.
ExerciseDirect20K shares at avg. $21.69$434K - Feb 18, 2026EXEL
EXELIXIS, INC.
SaleDirect44.1K shares at avg. $44.50$2.0M - Feb 17, 2026EXEL
EXELIXIS, INC.
SaleDirect42.4K shares at avg. $43.33$1.8M - Feb 17, 2026EXEL
EXELIXIS, INC.
ExerciseDirect42.4K shares at avg. $18.19$772K - Jun 3, 2025STOK
Stoke Therapeutics, Inc.
AwardDirectDirector Stock Option (Right to Buy)
29.7K shares- - May 29, 2025EXEL
EXELIXIS, INC.
AwardDirect9.8K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 3, 2026 |  STOK Stoke Therapeutics, Inc. | Award Director Stock Option (Right to Buy) | 17,786 | - | - | Direct |
| May 27, 2026 |  EXEL EXELIXIS, INC. | Award | 8,367 | - | $0 | Direct |
| Feb 18, 2026 | EXEL EXELIXIS, INC. | Exercise | 44,087 | $19.39 | $854,847 | Direct |
| Feb 18, 2026 | EXEL EXELIXIS, INC. | Sale | 20,030 | $44.30 | $887,329 | Direct |
| Feb 18, 2026 | EXEL EXELIXIS, INC. | Exercise | 20,030 | $21.69 | $434,451 | Direct |
| Feb 18, 2026 | EXEL EXELIXIS, INC. | Sale | 44,087 | $44.50 | $1,961,872 | Direct |
| Feb 17, 2026 | EXEL EXELIXIS, INC. | Sale | 42,422 | $43.33 | $1,838,145 | Direct |
| Feb 17, 2026 | EXEL EXELIXIS, INC. | Exercise | 42,422 | $18.19 | $771,656 | Direct |
| Jun 3, 2025 | STOK Stoke Therapeutics, Inc. | Award Director Stock Option (Right to Buy) | 29,747 | - | - | Direct |
| May 29, 2025 | EXEL EXELIXIS, INC. | Award | 9,812 | - | - | Direct |
1-10 of 15 transactions